Switch to:
Also traded in: Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.39
ALXN's Cash-to-Debt is ranked lower than
90% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. ALXN: 0.39 )
Ranked among companies with meaningful Cash-to-Debt only.
ALXN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.39  Med: 2.87 Max: No Debt
Current: 0.39
Equity-to-Asset 0.66
ALXN's Equity-to-Asset is ranked higher than
50% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ALXN: 0.66 )
Ranked among companies with meaningful Equity-to-Asset only.
ALXN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.27  Med: 0.66 Max: 0.93
Current: 0.66
0.27
0.93
Interest Coverage 6.88
ALXN's Interest Coverage is ranked lower than
88% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALXN: 6.88 )
Ranked among companies with meaningful Interest Coverage only.
ALXN' s Interest Coverage Range Over the Past 10 Years
Min: 6.88  Med: 128.41 Max: 292.93
Current: 6.88
6.88
292.93
Piotroski F-Score: 5
Altman Z-Score: 4.34
Beneish M-Score: -2.56
WACC vs ROIC
9.59%
4.34%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 21.63
ALXN's Operating Margin % is ranked higher than
87% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. ALXN: 21.63 )
Ranked among companies with meaningful Operating Margin % only.
ALXN' s Operating Margin % Range Over the Past 10 Years
Min: -138.47  Med: 25.18 Max: 38.9
Current: 21.63
-138.47
38.9
Net Margin % 12.77
ALXN's Net Margin % is ranked higher than
84% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. ALXN: 12.77 )
Ranked among companies with meaningful Net Margin % only.
ALXN' s Net Margin % Range Over the Past 10 Years
Min: -128.11  Med: 17.12 Max: 76.31
Current: 12.77
-128.11
76.31
ROE % 4.72
ALXN's ROE % is ranked higher than
80% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. ALXN: 4.72 )
Ranked among companies with meaningful ROE % only.
ALXN' s ROE % Range Over the Past 10 Years
Min: -81.59  Med: 14.48 Max: 63.11
Current: 4.72
-81.59
63.11
ROA % 3.01
ALXN's ROA % is ranked higher than
81% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. ALXN: 3.01 )
Ranked among companies with meaningful ROA % only.
ALXN' s ROA % Range Over the Past 10 Years
Min: -27.64  Med: 9.66 Max: 46.71
Current: 3.01
-27.64
46.71
ROC (Joel Greenblatt) % 47.67
ALXN's ROC (Joel Greenblatt) % is ranked higher than
91% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. ALXN: 47.67 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ALXN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -88.09  Med: 55 Max: 173.84
Current: 47.67
-88.09
173.84
3-Year Revenue Growth Rate 20.50
ALXN's 3-Year Revenue Growth Rate is ranked higher than
72% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. ALXN: 20.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ALXN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 33.55 Max: 462.4
Current: 20.5
0
462.4
3-Year EBITDA Growth Rate 18.90
ALXN's 3-Year EBITDA Growth Rate is ranked higher than
71% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. ALXN: 18.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ALXN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 18.9 Max: 73.2
Current: 18.9
0
73.2
3-Year EPS without NRI Growth Rate 11.50
ALXN's 3-Year EPS without NRI Growth Rate is ranked higher than
65% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. ALXN: 11.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ALXN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -19.4  Med: 11.5 Max: 76
Current: 11.5
-19.4
76
» ALXN's 10-Y Financials

Financials (Next Earnings Date: 2017-04-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

ALXN Guru Trades in Q2 2016

Paul Tudor Jones 13,329 sh (New)
Manning & Napier Advisors, Inc 95,050 sh (New)
Steven Cohen 529,500 sh (+517.85%)
Joel Greenblatt 58,459 sh (+447.16%)
John Paulson 268,000 sh (+70.48%)
David Carlson 190,000 sh (+18.75%)
Ron Baron 62,249 sh (+11.26%)
Pioneer Investments 41,387 sh (+0.23%)
Eaton Vance Worldwide Health Sciences Fund 396,700 sh (+77.89%)
Dodge & Cox Sold Out
Frank Sands 4,874,758 sh (-6.47%)
» More
Q3 2016

ALXN Guru Trades in Q3 2016

Paul Tudor Jones 153,511 sh (+1051.71%)
Steven Cohen 611,500 sh (+15.49%)
Manning & Napier Advisors, Inc 106,610 sh (+12.16%)
Frank Sands 5,245,752 sh (+7.61%)
David Carlson 190,000 sh (unchged)
Pioneer Investments 40,938 sh (-1.08%)
John Paulson 227,700 sh (-15.04%)
Joel Greenblatt 46,797 sh (-19.95%)
Ron Baron 44,260 sh (-28.90%)
Eaton Vance Worldwide Health Sciences Fund 183,684 sh (-53.70%)
» More
Q4 2016

ALXN Guru Trades in Q4 2016

Eric Mindich 202,000 sh (New)
Manning & Napier Advisors, Inc 1,324,444 sh (+1142.33%)
Pioneer Investments 52,228 sh (+27.58%)
David Carlson 220,000 sh (+15.79%)
Frank Sands 5,585,268 sh (+6.47%)
Eaton Vance Worldwide Health Sciences Fund 207,828 sh (+13.14%)
Eric Mindich 200,000 sh (unchged)
John Paulson 153,000 sh (unchged)
John Paulson 200,000 sh (unchged)
John Paulson 153,341 sh (-32.66%)
Steven Cohen 398,200 sh (-34.88%)
Ron Baron 20,470 sh (-53.75%)
Joel Greenblatt 13,966 sh (-70.16%)
Paul Tudor Jones 1,700 sh (-98.89%)
» More
Q1 2017

ALXN Guru Trades in Q1 2017

Spiros Segalas 3,232,001 sh (+25.20%)
Manning & Napier Advisors, Inc 1,105,568 sh (-16.53%)
» More
» Details

Insider Trades

Latest Guru Trades with ALXN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 8731
Compare:NAS:INCY, OTCPK:ALIOY, NAS:VRTX, OTCPK:GIKLY, NAS:BMRN, OTCPK:UCBJY, OTCPK:NVZMF, NAS:REGN, OTCPK:GMXAY, NAS:SGEN, NAS:JAZZ, OTCPK:CSLLY, NAS:ALKS, NAS:TSRO, NAS:BIVV, NAS:EXEL, OTCPK:SBMFF, NAS:IONS, NAS:UTHR, NAS:ARIA » details
Traded in other countries:AXP.Germany, ALXN.Mexico, ALXN.Switzerland, 0QZM.UK,
Headquarter Location:USA
Alexion Pharmaceuticals Inc is a biopharmaceutical company engaged in serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Alexion Pharmaceuticals specializes in the development and marketing of drugs for life-threatening medical conditions. The firm's blockbuster product is Soliris, the only approved therapy for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, two ultra-rare blood disorders. Strensiq and Kanuma also target other ultra-rare metabolic diseases. Alexion's pipeline targets areas of high unmet need and complement-mediated disorders.

Guru Investment Theses on Alexion Pharmaceuticals Inc

Spiros Segalas on Alexion Pharmaceuticals - Aug 18, 2016



Many Health Care stocks that have been strong positive contributors to return over past quarters continued to face concerns about drug pricing. Biotechnology companies that sell innovative, high priced drugs lost ground, including Alexion Pharmaceuticals (NASDAQ:ALXN). We believe that the long-term fundamentals of the Fund’s biotechnology holdings remain intact, and that current valuations underestimate the potential of pipeline drugs.





From Spiros Segamas' Armiel Appreciation second quarter 2016 commentary.



Check out Spiros Segalas latest stock trades

Baron Funds Comments on Alexion Pharmaceuticals - May 23, 2016

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) fell in the first quarter as a result of the significant correction in the biotech/pharma space. Alexion develops treatments for rare diseases. Its high foreign exchange exposure and high multiple also pressured the stock. Overall, we believe there have been no significant changes to the fundamentals of Alexion’s investment thesis (innovative, exceptionally well-managed company with unique assets and pricing power) and we retain conviction.



From Baron Fifth Avenue Growth Fund first quarter commentary 2016.



Check out Ron Baron latest stock trades

Baron Funds Comments on Alexion Pharmaceuticals - May 23, 2016

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) fell in the first quarter as a result of the significant correction in the biotech/pharma space. Alexion develops treatments for rare diseases. Its high foreign exchange exposure and high



From Baron Fifth Avenue Growth Fund first quarter commentary 2016.



Check out Ron Baron latest stock trades

Baron Funds Comments on Alexion Pharmaceuticals - May 06, 2016

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) fell sharply in the first quarter as a result of the massive correction in the biotech/pharma space. Alexion develops treatments for rare diseases. Its high foreign exchange exposure and high multiple also pressured the stock. Overall, we believe there have been no significant changes to the fundamentals of Alexion’s story and we retain conviction. (Josh Riegelhaupt)





From Baron Opportunity Fund first quarter 2016 commentary.







Check out Ron Baron latest stock trades

Baron Funds Comments on Alexion Pharmaceuticals - Feb 08, 2016

We also sold our Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) position in the third quarter to harvest a tax loss. We rebuilt our position this quarter. Alexion is the premier orphan disease company, whose lead product Soliris is a lifesaving medicine for both Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). The company has expanded its efforts in orphan diseases (particularly ones with high unmet needs) with the acquisition of Strensiq for Hypophosphatasia (HPP) and Kanuma for Lysosomal Acid Lipase Deficiency (LAL-D), both of which are approved or in the final stages of approval for launch worldwide.



From the Baron Funds Opportunity Fund fourth quarter 2015 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Alexion Pharmaceuticals Inc. - Nov 10, 2015

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is the premier orphan disease company, whose lead product Soliris is a lifesaving medicine for both Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical hemolytic uremic syndrome (aHUS). The company has expanded its efforts in orphan diseases (particularly ones with high unmet needs) with the acquisition of Strensiq for HPP (Hypophosphatasia) and Kanuma for LAL-D (Lysosomal Acid Lipase Deficiency), both of which are approved or in the final stages of approval for launch worldwide. The company recently announced the delay of Strensiq approval by the FDA for manufacturing related issues. With greater uncertainty surrounding the approval of Strensiq, and overall sentiment on the biotech industry souring, we reduced our exposure to the industry and sold our position in Alexion.





From the Baron Opportunity Fund third quarter 2015 letter.



Check out Ron Baron latest stock trades

Baron Funds Comments on Alexion Pharmaceuticals Inc. - Aug 19, 2015

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is a biopharmaceutical company that pioneered the “orphan disease” space by focusing on delivering life-transforming treatments for patients with devastating (life threatening) and ultra-rare (or orphan) diseases. Alexion is a leader in disease education and diagnostic initiatives to ensure that patients for its drugs are rapidly and accurately diagnosed. We believe Alexion’s first commercial drug, known as Soliris, which is used to treat paroxysmal nocturnal hemoglobinuria (called PNH) and atypical hemolytic uremic syndrome (referred to as aHUS), continues to possess a large global growth opportunity. Alexion has a pipeline of additional rare-disease treatments, and recently acquired Synageva, a company with two additional drugs for treating rare and devastating metabolic diseases, as well as a pipeline of other compounds, giving the company what we believe to be the most robust rare disease pipeline in the biotech industry.





From Baron Funds’ second quarter 2015 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Alexion Pharmaceuticals Inc

Arbutus Licenses LNP Delivery Technology to Alexion for Use in Single Messenger RNA Product Candidate

Agreement Calls for Upfront and Potential Milestone Payments of Over $80 Million Plus Royalties
VANCOUVER, British Columbia and DOYLESTOWN, Pa., March 16, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus (HBV) infection, today announced it has licensed to Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) its proprietary lipid nanoparticle (LNP) technology for exclusive use in one of Alexion’s rare disease programs. This transaction enables Alexion to address delivery for therapeutic application of messenger RNA (mRNA) and rapidly enter clinical development with its mRNA product candidate. 
Under the terms of the license agreement, Alexion will pay Arbutus $7.5 million upfront, and payments of up to $75 million for achievement of development, regulatory, and commercial milestones, as well as single digit royalties. In addition, Arbutus will conduct technology development and provide manufacturing and regulatory support for the rapid advancement of Alexion’s mRNA product candidate."This agreement validates our leadership position in LNP technology and underscores the value of this platform in enabling RNA therapeutics. We are excited to be working with Alexion to advance a treatment for rare disease," said Dr. Mark J. Murray, Arbutus’ President and CEO. "Our core focus as a company remains the cure of HBV.  This transaction with Alexion illustrates the value of our LNP platform, which has broad potential to deliver mRNA and gene editing therapeutics. We are receiving significant interest from companies that require access to our LNP platform to enable their own development programs. Our LNP expertise and intellectual property will contribute both near and long term value to Arbutus.”About Arbutus BiopharmaArbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Doylestown, PA. For more information, visit www.arbutusbio.com.Forward-Looking Statements and InformationThis press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements in this press release include statements about developing a cure for chronic hepatitis B virus (HBV) infection; enabling Alexion to address novel delivery challenges for their program; the terms of the licensing agreement between Arbutus and Alexion, including expected payments and royalties; and completing additional transactions to grant access to Arbutus’ LNP expertise and intellectual property. With respect to the forward-looking statements contained in this press release, Arbutus has made numerous assumptions regarding, among other things: the continued demand for Arbutus’ assets; the ability for Alexion to meet milestones; and the stability of economic and market conditions. While Arbutus considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.Additionally, there are known and unknown risk factors which could cause Arbutus' actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: Arbutus and Alexion may decide to amend the terms of their agreement; Alexion may not meet its development, regulatory, or commercial milestones; economic and market conditions may worsen; and market shifts may require a change in strategic focus.A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus' Annual Report on Form 10-K and Arbutus' continuous disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.
Contact Information
Investors
Adam Cutler
Senior Vice President, Corporate Affairs
Phone: 604.419.3200
Email: [email protected]

Media
David Schull
Russo Partners
Phone: 858.717.2310
Email: [email protected]

Read more...
Spiros Segalas on Alexion Pharmaceuticals Guru stock highlight
Many Health Care stocks that have been strong positive contributors to return over past quarters continued to face concerns about drug pricing. Biotechnology companies that sell innovative, high priced drugs lost ground, including Alexion Pharmaceuticals (NASDAQ:ALXN). We believe that the long-term fundamentals of the Fund’s biotechnology holdings remain intact, and that current valuations underestimate the potential of pipeline drugs.


From Spiros Segamas' Armiel Appreciation second quarter 2016 commentary. Read more...
Baron Funds Comments on Alexion Pharmaceuticals Guru stock highlight
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) fell in the first quarter as a result of the significant correction in the biotech/pharma space. Alexion develops treatments for rare diseases. Its high foreign exchange exposure and high Read more...
Baron Funds Comments on Alexion Pharmaceuticals Guru stock highlight
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) fell in the first quarter as a result of the significant correction in the biotech/pharma space. Alexion develops treatments for rare diseases. Its high foreign exchange exposure and high multiple also pressured the stock. Overall, we believe there have been no significant changes to the fundamentals of Alexion’s investment thesis (innovative, exceptionally well-managed company with unique assets and pricing power) and we retain conviction. Read more...
Baron Funds Comments on Alexion Pharmaceuticals Guru stock highlight
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) fell sharply in the first quarter as a result of the massive correction in the biotech/pharma space. Alexion develops treatments for rare diseases. Its high foreign exchange exposure and high multiple also pressured the stock. Overall, we believe there have been no significant changes to the fundamentals of Alexion’s story and we retain conviction. (Josh Riegelhaupt) Read more...

Ratios

vs
industry
vs
history
PE Ratio 72.84
ALXN's PE Ratio is ranked lower than
77% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 28.38 vs. ALXN: 72.84 )
Ranked among companies with meaningful PE Ratio only.
ALXN' s PE Ratio Range Over the Past 10 Years
Min: 13.83  Med: 76.8 Max: 961.82
Current: 72.84
13.83
961.82
Forward PE Ratio 22.73
ALXN's Forward PE Ratio is ranked lower than
61% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 18.05 vs. ALXN: 22.73 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 72.84
ALXN's PE Ratio without NRI is ranked lower than
77% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 29.63 vs. ALXN: 72.84 )
Ranked among companies with meaningful PE Ratio without NRI only.
ALXN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.71  Med: 76.65 Max: 705.33
Current: 72.84
13.71
705.33
Price-to-Owner-Earnings 46.63
ALXN's Price-to-Owner-Earnings is ranked lower than
59% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. ALXN: 46.63 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ALXN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 15.74  Med: 66.87 Max: 1108.89
Current: 46.63
15.74
1108.89
PB Ratio 3.28
ALXN's PB Ratio is ranked higher than
57% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. ALXN: 3.28 )
Ranked among companies with meaningful PB Ratio only.
ALXN' s PB Ratio Range Over the Past 10 Years
Min: 2.98  Med: 10.25 Max: 166.91
Current: 3.28
2.98
166.91
PS Ratio 9.36
ALXN's PS Ratio is ranked higher than
58% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. ALXN: 9.36 )
Ranked among companies with meaningful PS Ratio only.
ALXN' s PS Ratio Range Over the Past 10 Years
Min: 8.49  Med: 16.02 Max: 929.17
Current: 9.36
8.49
929.17
Price-to-Free-Cash-Flow 38.33
ALXN's Price-to-Free-Cash-Flow is ranked lower than
62% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. ALXN: 38.33 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ALXN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 34.77  Med: 61.66 Max: 3326.67
Current: 38.33
34.77
3326.67
Price-to-Operating-Cash-Flow 26.57
ALXN's Price-to-Operating-Cash-Flow is ranked lower than
57% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. ALXN: 26.57 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ALXN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 24.11  Med: 47.5 Max: 83.31
Current: 26.57
24.11
83.31
EV-to-EBIT 45.78
ALXN's EV-to-EBIT is ranked lower than
78% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. ALXN: 45.78 )
Ranked among companies with meaningful EV-to-EBIT only.
ALXN' s EV-to-EBIT Range Over the Past 10 Years
Min: -115.8  Med: 47 Max: 499.4
Current: 45.78
-115.8
499.4
EV-to-EBITDA 28.81
ALXN's EV-to-EBITDA is ranked lower than
64% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. ALXN: 28.81 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALXN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -145  Med: 41.95 Max: 258.3
Current: 28.81
-145
258.3
PEG Ratio 2.66
ALXN's PEG Ratio is ranked lower than
59% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 2.13 vs. ALXN: 2.66 )
Ranked among companies with meaningful PEG Ratio only.
ALXN' s PEG Ratio Range Over the Past 10 Years
Min: 0.68  Med: 1.81 Max: 11.71
Current: 2.66
0.68
11.71
Shiller PE Ratio 111.43
ALXN's Shiller PE Ratio is ranked lower than
72% of the 53 Companies
in the Global Biotechnology industry.

( Industry Median: 53.05 vs. ALXN: 111.43 )
Ranked among companies with meaningful Shiller PE Ratio only.
ALXN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 101.42  Med: 249.03 Max: 1466
Current: 111.43
101.42
1466
Current Ratio 3.13
ALXN's Current Ratio is ranked lower than
60% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. ALXN: 3.13 )
Ranked among companies with meaningful Current Ratio only.
ALXN' s Current Ratio Range Over the Past 10 Years
Min: 3.13  Med: 5.45 Max: 45.4
Current: 3.13
3.13
45.4
Quick Ratio 2.68
ALXN's Quick Ratio is ranked lower than
62% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. ALXN: 2.68 )
Ranked among companies with meaningful Quick Ratio only.
ALXN' s Quick Ratio Range Over the Past 10 Years
Min: 2.68  Med: 5.33 Max: 45.4
Current: 2.68
2.68
45.4
Days Inventory 467.39
ALXN's Days Inventory is ranked lower than
93% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. ALXN: 467.39 )
Ranked among companies with meaningful Days Inventory only.
ALXN' s Days Inventory Range Over the Past 10 Years
Min: 202.61  Med: 366.37 Max: 959.95
Current: 467.39
202.61
959.95
Days Sales Outstanding 76.93
ALXN's Days Sales Outstanding is ranked lower than
59% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. ALXN: 76.93 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALXN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 70.73  Med: 102.08 Max: 234.47
Current: 76.93
70.73
234.47
Days Payable 90.54
ALXN's Days Payable is ranked higher than
64% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. ALXN: 90.54 )
Ranked among companies with meaningful Days Payable only.
ALXN' s Days Payable Range Over the Past 10 Years
Min: 44.39  Med: 91.56 Max: 494.52
Current: 90.54
44.39
494.52

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.40
ALXN's 3-Year Average Share Buyback Ratio is ranked higher than
76% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. ALXN: -4.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALXN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -24.9  Med: -9.5 Max: -2.4
Current: -4.4
-24.9
-2.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.09
ALXN's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
66% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. ALXN: 2.09 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ALXN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 2.02  Med: 5.21 Max: 26.16
Current: 2.09
2.02
26.16
Price-to-Median-PS-Value 0.58
ALXN's Price-to-Median-PS-Value is ranked higher than
78% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. ALXN: 0.58 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALXN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.4  Med: 1.09 Max: 53.16
Current: 0.58
0.4
53.16
Price-to-Peter-Lynch-Fair-Value 2.89
ALXN's Price-to-Peter-Lynch-Fair-Value is ranked lower than
68% of the 66 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. ALXN: 2.89 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ALXN' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.56  Med: 2.9 Max: 9.91
Current: 2.89
0.56
9.91
Earnings Yield (Greenblatt) % 2.20
ALXN's Earnings Yield (Greenblatt) % is ranked higher than
75% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. ALXN: 2.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALXN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.2  Med: 2 Max: 3
Current: 2.2
0.2
3
Forward Rate of Return (Yacktman) % 27.89
ALXN's Forward Rate of Return (Yacktman) % is ranked higher than
73% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 16.45 vs. ALXN: 27.89 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ALXN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -18.5  Med: 0.5 Max: 75.6
Current: 27.89
-18.5
75.6

More Statistics

Revenue (TTM) (Mil) $3,084
EPS (TTM) $ 1.75
Beta1.39
Short Percentage of Float2.29%
52-Week Range $109.12 - 158.08
Shares Outstanding (Mil)225.15

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 3,493 4,145 4,906
EPS ($) 5.38 7.25 9.13
EPS without NRI ($) 5.38 7.25 9.13
EPS Growth Rate
(Future 3Y To 5Y Estimate)
14.63%
Dividends per Share ($)
» More Articles for ALXN

Headlines

Articles On GuruFocus.com
Arbutus Licenses LNP Delivery Technology to Alexion for Use in Single Messenger RNA Product Candidat Mar 16 2017 
Spiros Segalas on Alexion Pharmaceuticals Aug 18 2016 
Spiros 'Sig' Segalas' Capital Appreciation Fund 2nd Quarter Commentary Nov 07 2016 
Frank Sands Sells Visa, Baidu, Alibaba May 24 2016 
Baron Funds Comments on Alexion Pharmaceuticals May 23 2016 
Baron Funds Comments on Alexion Pharmaceuticals May 23 2016 
Baron Funds Comments on Alexion Pharmaceuticals May 06 2016 
Baron Funds Comments on Alexion Pharmaceuticals Feb 08 2016 
Weekly CFO Sales Highlight: H&R Block, DISH Network, Alexion Pharmaceuticals Jan 03 2016 
Weekly CFO Sells Highlight: Tyson Foods, Alexion Pharmaceuticals, Gilead Sciences Dec 13 2015 

More From Other Websites
Celgene Stock Dips On Mixed Q1 As Earnings Top But Sales Miss Apr 27 2017
Alexion Crushes Wall Street's Revenue, Profit Expectations Apr 27 2017
Biotech Movers: Pacific Biosciences Falls After Net Loss Spikes Apr 27 2017
Alexion beats Street 1Q forecasts Apr 27 2017
Alexion Reports First Quarter 2017 Results Apr 27 2017
Is This Why Akari Therapetuics PLC Is Falling Today? Apr 24 2017
Street Watches To See If $125,000 Drug Boosts Biogen's Results Apr 21 2017
Alexion (ALXN) Q1 Earnings: Can the Stock Pull a Surprise? Apr 21 2017
What to expect from biotech Apr 20 2017
Gilead Sciences: Who's Frustrated Now? Apr 19 2017
3 Beaten-Up Healthcare Stocks: Are They Bargains? Apr 19 2017
The 7 Most Expensive Prescription Drugs in the World Apr 18 2017
3 Big Reasons to Be Bullish on Biotech Stocks Apr 16 2017
The Hot Stock: Alexion Pharmaceuticals Climbs 3.3% Apr 13 2017
[$$] Celgene, Biogen to Gain From Higher Prices Apr 12 2017
Alexion to Report First Quarter 2017 Results on Thursday, April 27, 2017 Apr 06 2017
Alexion Pharmaceuticals Slid 9.9% in March -- but Why? Apr 04 2017
[$$] Beaten-Down Biotechs May Be Worth Buying Apr 04 2017
3 Top Growth Stocks Priced at a Bargain This Spring Apr 03 2017
Akari Gets Fast Track Status for Coversin Drug Mar 31 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)